Linagliptine (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Linagliptine" in French language version.

refsWebsite

Global rank French rank

222^nd place

129^th place

2,393^rd place

506^th place

1,735^th place

168^th place

274^th place

223^rd place

1jamanetwork.com

2,650^th place

689^th place

1ahajournals.org

3,608^th place

659^th place

low place

2,283^rd place

ahajournals.org

McGuire DK, Alexander JH, Johansen OE et al. Linagliptin effects on heart failure and related outcomes in individuals with type 2 diabetes mellitus at high cardiovascular and renal risk in CARMELINA, Circulation, 2019;139:351–361

jamanetwork.com

Rosenstock J, Perkovic V, Johansen OE et al. Effect of Linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk. The CARMELINA randomized clinical trial, JAMA, 2019;321:69-79

prescrire.org

« Linagliptine (Trajenta°, et associée avec la metformine dans Jentadueto°) - un médicament à écarter des soins », sur prescrire.org (consulté le 13 décembre 2022)

qmul.ac.uk

chem.qmul.ac.uk

Masse molaire calculée d’après « Atomic weights of the elements 2007 », sur www.chem.qmul.ac.uk.

springer.com

link.springer.com

Graefe-Mody U, Retlich S, Friedrich C, Clinical pharmacokinetics and pharmacodynamics of linagliptin, Clin Pharmacokinet, 2012;51:411-427

thelancet.com

Gallwitz B, Rosenstock J, Rauch T et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial, Lancet, 2012;380:475-483
Barnett AH, Huisman H, Jones R, von Eynatten M, Patel S, Woerle H-J, Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial, Lancet, 2013;382:1413-1423

wiley.com

onlinelibrary.wiley.com

Del Prato S, Barnett AH, Huisman H, Neubacher D, Woerle HJ, Dugi KA, Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial, Diabetes Obes Metab, 2011;13:258-267
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA, Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 2011;13:653-661
Taskinen MR, Rosenstock J, Tamminen I et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study, Diabetes Obes Metab, 2011;13:65-74
Owens DR, Swallow R, Dugi KA, Woerle HJ, Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study, Diabet Med, 2011;28:1352-1361